$BCTXL News
Last published 5d ago
- 5d agoBCTXLBCTXZBCTXWBCTXBriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026GlobeNewswireBria-OTS+™ demonstrates broad immune activation and sustained cancer-cell killing across multiple tumor modelsBriaPro data highlights BP-80 tolerability in...
- 5d agoBCTXBCTXWBCTXZBCTXLBriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026GlobeNewswireBria-OTS+™ demonstrates broad immune activation and sustained cancer-cell killing across multiple tumor modelsBriaPro data highlights BP-80 tolerability in primates and advances in tumor-targeted checkpoint inhibition
- 1w agoBCTXBCTXWBCTXZBCTXLBriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026GlobeNewswireFour presentations highlight BriaCell’s Bria-OTS+™ cellular immunotherapy platform and BriaPro’s CD80-based immunotherapy programsIn vitro Bria-OTS+ studies demonstrate immune-cell activation and tumor-cell killing
- 2w agoBCTXBCTXWBCTXZBCTXLBriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast CancerGlobeNewswireDynamic changes in PD-L1 expression on circulating cancer-associated macrophage-like cells (CAML) were significantly associated with progression-free survival and overall survival following immunotherapies including the
- 1mo agoBCTXBCTXWBCTXZBCTXLData Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer StudyGlobeNewswireIndependent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitorSeventh consecutive positive DSMB recommendation
- 2mo agoBCTXBCTXWBCTXZBCTXLBriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer CenterGlobeNewswireNow Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" PHILADELPHIA and VANCOUVER,
- 2mo agoBCTXBCTXWBCTXZBCTXLBriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™GlobeNewswireCell-based immunotherapy program is designed to harness patients’ own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without
- 3mo agoBCTXBCTXWBCTXZBCTXLBriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate CancerGlobeNewswireFDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell’s next generation personalized immunotherapy for
- 3mo agoBCTXBCTXWBCTXZBCTXLBriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast CancerGlobeNewswireSunnybrook’s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell’s pivotal Phase 3 clinical trial in metastatic breast cancerBriaCell Phase 3 trial featured in Nature Medicine
- 3mo agoBCTXBCTXWBCTXZBCTXLBriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™GlobeNewswireArrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell’s pivotal Phase 3 study and commercial scalability potential Bria-IMT is currently being evaluated in
- 4mo agoBCTXBCTXWBCTXZBCTXL+1BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™GlobeNewswireCharles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the USKaleio to support brand strategies and customized
- 4mo agoBCTXBCTXWBCTXZBCTXLBriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™GlobeNewswireAgreement supports potential commercial readiness for Bria-IMT using Uneedle’s proprietary microneedle technology for intradermal administration Technology is currently used in BriaCell’s pivotal Phase 3 study and is
- 5mo agoBCTXBCTXLBCTXWBCTXZBriaCell Therapeutics Announces Closing of OfferingGlobeNewswirePHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company
- 5mo agoBCTXBCTXLBCTXWBCTXZBriaCell Presents Positive Clinical Data at ASCO 2026GlobeNewswireFinal Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) patients treated with Bria-IMT regimen selected for Phase 3TWiST analysis, which
- 5mo agoBCTXBCTXLBCTXWBCTXZBriaCell Therapeutics Announces Pricing of OfferingGlobeNewswirePHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company
- 5mo agoBCTXBCTXLBCTXWBCTXZBriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast CancerGlobeNewswireIndependent DSMB has identified no safety concerns, to date, and recommends continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitorSixth consecutive positive DSMB
- 5mo agoBCTXBCTXLBCTXWBCTXZBriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026GlobeNewswireFinal Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ongoing Phase 3 study in heavily pre-treated metastatic breast cancer (MBC)
- 6mo agoBCTXBCTXLBCTXWBCTXZBriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™GlobeNewswireBriaCell expands push in women's health, building on Phase 2 success in advanced metastatic breast cancerBria-OVA+, BriaCell's next generation personalized immunotherapy candidate for ovarian cancer, is designed with
- 6mo agoBCTXBCTXLBCTXWBCTXZBriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate CancerGlobeNewswireBria-PROS+ is BriaCell's next generation personalized off-the-shelf immunotherapy for prostate cancerImmune stimulating components of Bria-PROS+ enhance anti-tumor responsesBriaCell has completed manufacturing clinical
- 6mo agoBCTXBCTXLBCTXWBCTXZBriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer StudyGlobeNewswireOther recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia (UVA) Comprehensive Cancer Center, Baptist Health South Florida, and SCRI Oncology
- 6mo agoBCTXBCTXLBCTXWBCTXZBriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 PatientsGlobeNewswireOver 315 patients screened and over 230 patients enrolled in BriaCell's pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer Enrollment momentum continues with strong
- 6mo agoBCTXBCTXLBCTXWBCTXZBriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer StudyGlobeNewswirePHILADELPHIA and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company
- 6mo agoBCTXBCTXLBCTXWBCTXZBriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast CancerGlobeNewswireFDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancerBria-BRES+ is BriaCell's next generation personalized immunotherapy
- 6mo agoBCTXBCTXLBCTXWBCTXZBriaCell Announces Six Clinical Data Presentations at ASCO 2026GlobeNewswireFinal randomized Phase 2 Bria-IMT™ survival and quality of life data to be presentedBiomarker analyses from the ongoing Phase 3 study evaluating predictors of response PHILADELPHIA and VANCOUVER, British
- 6mo agoBCTXBCTXLBCTXWBCTXZBriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer ModelsGlobeNewswireBria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line modelsImmune cells activated by Bria-OTS+ exhibit serial killing activity across multiple
- 6mo agoBCTXBCTXLBCTXWBCTXZBriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR MeetingGlobeNewswirePhase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4/6 inhibitor treatments shows quality of life (QOL) largely preservedIdentification of potential
- 7mo agoBCTXBCTXLBCTXWBCTXZBriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 LicenseGlobeNewswirePHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL)) (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology company that
- 8mo agoBCTXBCTXLBCTXWBCTXZBriaCell to Present Four Poster Presentations at the 2026 AACR Annual MeetingGlobeNewswirePHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company
- 8mo agoBCTXBCTXLBCTXWBCTXZBriaCell Therapeutics Corp. Announces Results of Shareholder MeetingGlobeNewswirePHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL), BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company
- 8mo agoBCTXBCTXLBCTXWBCTXZBriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 LicenseGlobeNewswirePHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL)) (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology company that
- 8mo agoBCTXBCTXLBCTXWBCTXZBriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast CancerGlobeNewswireIndependent DSMB has identified no safety concerns, and recommends continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitorFifth consecutive positive DSMB recommendation
- 9mo agoBCTXBCTXLBCTXWBCTXZBriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune ActivationGlobeNewswireImages below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to dateBria-IMT regimen continues
- 9mo agoBCTXBCTXLBCTXWBCTXZBriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer PatientsGlobeNewswire9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT™ related
- 10mo agoBCTXBCTXLBCTXWBCTXZBriaCell Therapeutics Announces Closing of US$30 million Public OfferingGlobeNewswirePHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that